A Robust and Universal LC–MS/MS Method for Determination of N ‐Nitrosodimethylamine in Pharmaceuticals Using a C30 Column
Authors:
Open Access
- 12 June 2026
- journal article
- Published by Wiley in Journal of Separation Science
- Vol. 49 (6) , e70465
Abstract
Since the 2018 valsartan recall, the genotoxic impurity N‐ nitrosodimethylamine (NDMA) has been frequently detected in various pharmaceuticals. Matrix variability often complicates routine testing, requiring customized analyses. We developed a universal LC–MS/MS method enabling consistent NDMA detection across diverse pharmaceuticals. Separation utilized a C30 column (150 mm × 4.6 mm I.D., 5 µm), offering superior retention and shape selectivity for polar nitrosamines compared to conventional reversed phases. Unlike C18 or pentafluorophenyl phases, which often exhibit limited retention for NDMA, the C30 phase provides exceptional shape selectivity and enhanced hydrophobic interactions. This structural advantage, supplemented by its resistance to phase dewetting under highly aqueous conditions further ensures robust resolution between NDMA and complex drug matrices. The mobile phase consisted of 0.1% v/v formic acid in water and methanol under gradient elution at 1.0 mL/min. Detection used atmospheric pressure chemical ionization in positive ion mode. The method demonstrated a linear range of 2.0–100.0 ng/mL ( r 2 > 0.999), with a limit of detection of 1.0 ng/mL and a limit of quantification of 2.0 ng/mL. Validation per International Council for Harmonisation (ICH) guidelines confirmed accuracy (87.7%–115.5%) and precision (coefficient of variation, CV ≤ 10.7%). Application to 30 diverse pharmaceutical products, including sartans and ranitidine, showed robust resolution (> 2.0) between the analyte and active pharmaceutical ingredients (APIs). Notably, NDMA was quantified in historical batches of ranitidine (164.83 ± 5.68 ng/mL), nizatidine (10.25 ± 0.52 ng/mL), and amitriptyline (2.28 ± 0.19 ng/mL). While the histamine type 2 receptor antagonists significantly exceeded the acceptable daily intake limit, the remaining 27 products showed no detectable NDMA. These findings highlight the method's effectiveness for real‐world surveillance and the critical risk of post‐manufacturing NDMA generation during prolonged storage. This universal C30‐based method provides a practical, reliable tool for routine screening, facilitating regulatory compliance and improved patient safety without drugspecific method development.Keywords
Funding Information
- Ministry of Food and Drug Safety (20173MFDS162F)
- Ministry of Food and Drug Safety (23194MFDS086)
- Kementerian Pendidikan (2021R1A6A1A03044296)
This publication has 31 references indexed in Scilit:
- Basic considerations to minimize bias in collection and analysis of volatile methyl siloxanes in environmental samplesScience of The Total Environment, 2022
- An improved analytical method for quantitation of nitrosamine impurities in ophthalmic solutions using liquid chromatography with tandem mass spectrometryJournal of Chromatography Open, 2022
- NDMA analytics in metformin products: Comparison of methods and pitfallsEuropean Journal of Pharmaceutical Sciences, 2022
- Insight into the formation of N-nitrosodimethylamine in metformin productsJournal of Pharmaceutical and Biomedical Analysis, 2021
- Development of a new methodology for the determination of N-nitrosamines impurities in ranitidine pharmaceuticals using microextraction and gas chromatography-mass spectrometryTalanta, 2021
- Determination of N-nitrosodimethylamine and N-nitrosomethylethylamine in drug substances and products of sartans, metformin and ranitidine by precipitation and solid phase extraction and gas chromatography–tandem mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 2020
- Enhancement of volatile profiling using multiple-cumulative trapping solid-phase microextraction. Consideration on sample volumeAnalytica Chimica Acta, 2020
- The contamination of valsartan and other sartans, part 1: New findingsJournal of Pharmaceutical and Biomedical Analysis, 2019
- NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N-nitrosaminesJournal of Pharmaceutical and Biomedical Analysis, 2019
- A polar-embedded C30 stationary phase: Preparation and evaluationJournal of Chromatography A, 2015